RxSight announced that Aziz Mottiwala will become President and CEO effective July 20, 2026, succeeding Ron Kurtz, who will continue as Chief Medical Officer. Mottiwala previously served as Chief Commercial Officer at Tarsus Pharmaceuticals and Opiant Pharmaceuticals, and spent over a decade at Allergan in senior eye care leadership roles. The company also provided preliminary second-quarter 2026 revenue of $32 to $34 million, including $5 to $7 million from a recent Alcon collaboration, compared with $33.6 million a year earlier. For the full year 2026, RxSight expects total revenue of $140 to $160 million, but standalone sales excluding Alcon-based revenue are projected at $110 to $120 million, down from prior guidance of $120 to $135 million. Cash and short-term investments stood at approximately $209 million as of June 30, 2026.
Rxsight IncCut standalone 2026 sales outlook from $120-135M to $110-120M
Alcon AG
Tarsus Pharmaceuticals Inc